An economic evaluation for prevention of diabetes mellitus in a developing country: a modelling study

BMC Public Health

Table 4 The clinical and economic outcomes of prevention strategies and control (or compared with control) for subjects at different initiation ages

	Screening with diet intervention	Screening with exercise intervention	Screening with duo-intervention	Screening alone	Control
Initiation age of 25
Remaining life years^I	30.7	30.7	30.7	30.2	29.0
Costs (US$)^II	13294.77	13234.20	13241.38	18973.08	20102.87
Costs (US$)^II	(2750.37 - 27317.10)	(2744.20 - 27306.59)	(2745.42 - 27311.41)	(3755.50 - 33613.01)	(5334.50 - 37291.10)
Saving costs(US$)^III	6808.10	6868.67	6861.49	1129.79	−
QALYs^IV	17.98	17.98	17.98	17.05	14.65
QALYs^IV	(13.00 - 21.40)	(13.10 - 23.40)	(13.00 - 22.60)	(13.20 - 23.00)	(11.22 - 19.56)
Increment QALYs^III	3.33	3.33	3.33	2.40	−
Initiation age of 40
Remaining life years^I	20.1	20.1	20.1	19.7	19.6
Costs (US$)^II	9669.80	9659.97	9731.08	13180.33	13634.36
Costs (US$)^II	(2107.23 - 20052.17)	(2106.35 - 20048.25)	(2109.00 - 20055.12)	(3161.46 - 26225.65)	(4648.40 - 29925.24)
Saving costs(US$)^III	3964.56	3974.39	3903.28	454.03	−
QALYs ^IV	15.47	15.46	15.47	14.25	12.88
QALYs ^IV	(7.96 - 17.56)	(7.76 - 17.56)	(7.96 - 17.56)	(6.84 - 15.64)	(6.59 - 15.19)
Increment QALYs^III	2.59	2.58	2.59	1.37	−
Initiation age of 60
Remaining life years^I	7.5	7.5	7.5	7.4	7.4
Costs (US$)^II	5983.39	5921.23	5928.73	7606.03	8000.42
Costs (US$)^II	(1126.44 - 9436.12)	(1119.18 - 9425.71)	(1119.22 - 9429.12)	(1939.74 - 10312.51)	(2557.1 -16952.10)
Saving costs(US$)^III	2017.03	2079.19	2071.69	394.39	−
QALYs^IV	6.32	6.32	6.32	6.09	5.76
QALYs^IV	(4.26 - 11.33)	(4.26 - 11.19)	(4.30 - 11.23)	(3.41 - 10.12)	(3.35 - 9.65)
Increment QALYs^III	0.56	0.56	0.56	0.33	−

^I: The figures were the mean values of remaining survival years per subject with IGT or diabetes. ^II: Costs (US$) were the average cost (95% credible intervals) per subject, which arise for subjects from prevention and treatments of diabetes-related disorders during 40 years. ^III: Saving costs were the average cost per subject in prevention groups in comparison with that of control; Increment QALYs were the average QALYs per subject diagnosed with IGT or diabetes in prevention groups in comparison with that of control. ^IV: QALYs were the average QALYs per subject with IGT or diabetes (95% credible intervals).

ISSN: 1471-2458